Skip to content
GeoClinicalTrials
Back to search

NCT07600749Recruiting

Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)

Official recordSimplified version

Summary

Researchers are looking for new ways to treat certain types of advanced and/or metastatic solid tumors. The main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.

Inclusion criteria

• Has a histologically or cytologically confirmed diagnosis of 1 of the following unresectable (locally advanced) and/or advanced (metastatic) solid tumors: • Colorectal carcinoma (CRC) • Renal cell carcinoma (RCC) that contains a clear cell component (with or without sarcomatoid and/or rhabdoid features) • Nonsquamous non-small cell lung cancer (NSCLC) • Biliary tract cancer (BTC) (intra-or extrahepatic cholangiocarcinoma (CCA)) or gallbladder cancer (GBC) • Has measurable disease by Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) • Has adequate organ function • Participants with human immunodeficiency virus (HIV) infection must have well controlled HIV on stable antiretroviral therapy (ART) for at least 4 weeks • Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load • Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable

Exclusion criteria

• Has gastrointestinal malabsorption, a surgical procedure or a condition that could affect the absorption of the study drug • Has a history of clinically significant cardiac, cardiovascular and/or cerebrovascular disease • Has a serious nonhealing wound, ulcer, or bone fracture • Has an active infection(s) requiring systemic therapy • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease • Known additional malignancy that is progressing or has required active treatment within the past 2 years • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis • Has a history of stem cell/solid organ transplant • Has not adequately recovered from major surgery

Contacts

The trial team's contact details are shown on request.

See the official trial record
Status
Recruiting
Phase
Phase 1
Study type
Interventional
Countries
Switzerland, United States, Canada, Israel, Japan
Sponsor
Merck Sharp & Dohme LLC(Industry)
Protocol no.
4884-001
Conditions
Malignant Neoplasm
Interventions
Drug

Treatments studied

  • MK-4884

Locations · 10

  • Sankt Gallen, SwitzerlandCantonal Hospital St.Gallen ( Site 0101)Recruiting at this site
  • Lausanne, SwitzerlandCHUV (centre hospitalier universitaire vaudois) ( Site 0103)Recruiting at this site
  • Bellinzona, SwitzerlandOspedale Regionale Bellinzona e Valli ( Site 0104)Recruiting at this site
  • St Louis, United StatesSiteman Cancer Center ( Site 0153)Recruiting at this site
  • San Antonio, United StatesNEXT Oncology ( Site 0151)Recruiting at this site
  • Toronto, CanadaPrincess Margaret Cancer Centre ( Site 0004)Recruiting at this site
  • Montreal, CanadaCentre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0002)Recruiting at this site
  • Haifa, IsraelRambam Health Care Campus ( Site 0051)Recruiting at this site
  • Petah Tikva, IsraelRabin Medical Center ( Site 0053)Recruiting at this site
  • Chūō, JapanNational Cancer Center Hospital ( Site 0201)Recruiting at this site

In total, worldwide, all 10 sites listed in the registry are recruiting.

Site status per the ClinicalTrials.gov registry (last update posted: October 6, 2026).

This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.

See also

Other versions

These results are indicative and do not replace medical advice — discuss them with your doctor.